Skip to main content
. 2020 Apr 8;15(4):e0230898. doi: 10.1371/journal.pone.0230898

Fig 1.

Fig 1

A: Number of orphan drug designations (open bars) and FDA approvals (full bars) for compounds intended to treat lysosomal storage diseases by year. * indicates close of database: 10 May 2019. B: Overall number of orphan drug designations (open bars) and FDA approvals (full bars) by year. * indicates close of database: 10 May 2019.